Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib/Abiraterone Acetate and Prednisone for mCRPC with SPOP Mutation
NCT05689021Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Mar 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib + abiraterone acetate in castration-resistant prostate cancer (CRPC), sponsored by Mayo Clinic. Primary endpoint: Prostate Specific Antigen Response Rate at 13 months. Started Mar 2024; status: terminated.
02
Drugs
niraparib + abiraterone acetate
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05689021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689021.